Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variant of hepatitis B virus with primary resistance to adefovir.

The New England journal of medicine - 27 Apr 2006

Schildgen Oliver, Sirma Hueseyin, Funk Anneke, Olotu Cynthia, Wend Ulrike C, Hartmann Heinz, Helm Martin, Rockstroh Jürgen K, Willems Wulf R, Will Hans, Gerlich Wolfram H

Abstract excerpt

The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lamivudine

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Share to Tenofovir

Share to Viremia

Source

Identifiers

PMID: 16641397
DOI: 10.1056/NEJMoa051214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variant of hepatitis B virus with primary resistance to adefovir.PMID 16641397Read ↗

Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir.Semantic proximity Read ↗

Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.Semantic proximity Read ↗

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Semantic proximity Read ↗

HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.Semantic proximity Read ↗

Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.Semantic proximity Read ↗

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.Semantic proximity Read ↗

Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina.Semantic proximity Read ↗

Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases.Semantic proximity Read ↗

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.Semantic proximity Read ↗

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.Semantic proximity Read ↗

A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.Semantic proximity Read ↗

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.